InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,240.03
(
1.04%
)
US TECH 100
17,481.60
(
0.38%
)
Dow Jones
38,997.66
(
0.76%
)
Brent Oil
76.26
(
0.31%
)
Bitcoin
56,976.12
(
1.66%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

grandma_of_jbraika

Send PM Follow Ignore
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

grandma_of_jbraika

Re: Jesspro post# 42861

Monday, 12/30/2013 12:24:59 PM

Monday, December 30, 2013 12:24:59 PM

Post# of 80490
The post I quoted starts with "The next molecule ...". 113 is not the next molecule. Isn't it clear enough?

They are no long pursuing egfr.

False!

Stopping enrollment of patients with EGFR, T790M, ROS1 and other non-ALK tumor types in the ongoing clinical development of AP113 as part of cost reduction has nothing to do with the 'New Molecule'. The topic is the 'New Molecule', not AP26113.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up